It is important for emergency physicians to know that patients who had COVID‑19 infection but not confirmed or not tested can visit the emergency department due to complications of COVID‑19 infection such as thromboembolic events primarily.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Coronavirus disease 2019 (COVID‑19) disease leads to a hypercoagulable state and associated with thrombotic events that can cause mortality and morbidity.
📊
Key Findings & Data:In this case report, we present a 68‑year‑old COVID‑19 patient with multisystemic infarction who was admitted to the hospital by splenic infarction and later pulmonary embolism diagnosed during the stay in hospital despite anticoagulant use.
💡
Conclusion & Impact:It is important for emergency physicians to know that patients who had COVID‑19 infection but not confirmed or not tested can visit the emergency department due to complications of COVID‑19 infection such as thromboembolic events primarily.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters
Özet
Coronavirus disease 2019 (COVID‑19) disease leads to a hypercoagulable state and associated with thrombotic events that can cause mortality and morbidity. Thrombotic events include both venous and arterial thrombosis. In this case report, we present a 68‑year‑old COVID‑19 patient with multisystemic infarction who was admitted to the hospital by splenic infarction and later pulmonary embolism diagnosed during the stay in hospital despite anticoagulant use. It is important for emergency physicians to know that patients who had COVID‑19 infection but not confirmed or not tested can visit the emergency department due to complications of COVID‑19 infection such as thromboembolic events primarily.
🔖
Cite This Article
YILDIZ, E., SATILMIŞ, D., ÇEVİK, E. (2021). Splenic infarction and pulmonary embolism as a rare manifestation of COVID‑19. Turkish journal of emergency medicine (Online), Cilt: 21 - Sayı: 4, 214–218. https://ajindex.com/articles/417311
Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020;135:2033-40
JacksonSP, Darbousset R, SchoenwaelderSM. Thromboinflammation: Challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 2019;133:906-18
Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. JThromb Haemost 2020;18:1559-61
Santos Leite Pessoa M, Franco Costa Lima C, Farias Pimentel AC, Godeiro Costa JC, Bezerra Holanda JL. Multisystemic infarctions in COVID-19: Focus on the spleen. Eur J Case Rep Intern Med 2020;7:001747
Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145-7
Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, BergerJS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA 2020;324:799-801
Ramanathan M, Chueng T, Fernandez E, Gonzales-Zamora J. Concomitant renal and splenic infarction as a complication of COVID-19: A case report and literature review. Infez Med 2020;28:611-5
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available from: https://www.covid19treatmentguidelines.nih.gov/. [Last accessed on 2020 Dec 18].